Research in Connecticut
- 1 of 3
- next ›
This report shows that biopharmaceutical research com-panies continue to be vitally important to the economy and patient health in Connecticut, despite the recession.
At a time when the state still faces significant economic challenges, biopharmaceutical research companies are conducting or have conducted more than 2,000 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals. Of the more than 2,000 clinical trials, 1,043 target or have targeted the nation’s six most debilitating chronic diseases—asthma, cancer, diabetes, heart disease, mental illnesses and stroke.